Enable JavaScript to visit this website.

Already received the first dose of TRUMENBA?

Teens and young adults must complete all recommended doses of TRUMENBA to be fully vaccinated against MenB. Get text reminders for the next dose



TRUMENBA is an FDA-approved vaccine for meningitis B (also known as MenB)1

MenB is an uncommon but potentially deadly disease that progresses quickly and can lead to death within 24 hours.2,3

There are multiple strains of MenB. TRUMENBA has been shown to help protect teens from the most common strains of MenB.1,4

Teens and young adults between ages 16 and 23 may be at higher risk for MenB. You can help protect your teen by vaccinating with TRUMENBA.1,5 Talk to your health care provider or pharmacist today.

TRUMENBA helps protect your teen when they need it most5,6

In adolescents and young adults, the incidence of MenB peaks at age 19, so if your child is between 16 and 23, they may be at higher risk.5

TRUMENBA is the only vaccine tested against diverse MenB strains, including those found in meningitis outbreaks.1,4*

Why risk it? MenB is rare but has devastating consequences.3,7 Prep for a doctor's appointment with a Doctor Discussion Guide found at the link below. Then, talk to your doctor about the importance of vaccinating your teen or young adult.

*TRUMENBA was tested against diverse MenB strains expressing factor H binding protein subfamilies A and B. Two-dose effectiveness against diverse strains has not been confirmed.1

trumenba help

Two different vaccines are needed to fully vaccinate your teen or young adult against meningitis

There are 5 primary types of bacteria that cause meningitis (also known as meningococcal disease) and for which vaccines are available in the US: A, C, W, Y, and B.8

The Centers for Disease Control and Prevention (CDC) recommends vaccination for types A, C, W, and Y at ages 11 to 12, and a booster at age 16. The CDC recommends deciding with your doctor about vaccinating your child against MenB. The CDC-recommended age for MenB vaccination is 16 to 23 years (preferred age 16 to 18 years).9,10

You can help protect your teen by vaccinating with TRUMENBA, which is FDA approved for MenB.1

Routine visits with your child's doctor are a good opportunity to discuss the risks and potential serious side effects of MenB.7 Make sure you know whether your teen has received both types of meningitis vaccines, and whether they are protected against MenB.

map icon

Find TRUMENBA near you

arrowUse my current location Find it! Oops! Please enter a valid ZIP code
locator icon
TRUMENBA offers a vaccine reminder program

Sign up to help ensure your teen or young adult gets all recommended doses.

Get text reminders
  • Trumenba should not be given to anyone with a history of a severe allergic reaction after a previous dose of Trumenba
  • Some individuals with weakened immune systems may have a reduced immune response
  • Persons with certain complement deficiencies and persons receiving treatments such as Soliris® (eculizumab), are at increased risk for invasive disease caused by Neisseria meningitidis group B even with receipt of vaccination with Trumenba
  • As with any vaccine, vaccination with Trumenba may not protect all vaccine recipients against N meningitidis group B infections
  • Fainting can occur in association with administration of injectable vaccines, including Trumenba
  • The most common adverse reactions in adolescents and young adults were pain at injection site, fatigue, headache, and muscle pain. Nausea was reported in adolescents in early phase studies
  • Data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series
  • Tell your health care provider if you are pregnant, or plan to become pregnant
  • Ask your health care provider about the risks and benefits of Trumenba. Only a health care provider can decide if Trumenba is right for you or your child
  • Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B
  • The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis group B strains has not been confirmed

Patients should always ask their doctors for medical advice about adverse events.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

  1. TRUMENBA [package insert]. Philadelphia, PA: Pfizer Inc.; 2019.
  2. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403.
  3. Soeters HM, McNamara LA, Whaley M, et al. Serogroup B meningococcal disease outbreak and carriage evaluation at a college—Rhode Island, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(22):606-607.
  4. Wang X, Cohn A, Comanducci M, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine. 2011;29(29-30):4739-4744.
  5. National Foundation for Infectious Diseases. Addressing the challenges of serogroup B meningococcal disease outbreaks on campuses: a report by the National Foundation for Infectious Diseases. https://www.nfid.org/wp-content/uploads/2019/08/meningococcal-b-report.pdf. Published May 2014. Accessed March 11, 2020.
  6. Patton ME, Stephens D, Moore K, et al. Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine–Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(19):509-513.
  7. Bettinger JA, Scheifele DW, Le Saux N, et al. The disease burden of invasive meningococcal serogroup B disease in Canada. Pediatr Infect Dis J. 2013;32(1):e20-e25.
  8. McNeil LK, Zagursky RJ, Lin SL, et al. Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease. Microbiol Mol Biol Rev. 2013;77(2):234-252.
  9. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger: United States, 2020. Centers for Disease Control and Prevention website. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf. Updated January 29, 2020. Accessed March 10, 2020.
  10. MacNeil JR, Rubin L, Folaranmi T. Use of serogroup B meningococcal vaccines in adolescents and young adults: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(41):1171-1176.
Back to top